Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by ScienceFirston Oct 09, 2022 11:55am
216 Views
Post# 35014794

Ruthenium rips apart everything it happens to encounter

Ruthenium rips apart everything it happens to encounter
Considering this 2010 comment on Ruthenium attribute (*1), from Prof. Thomas Kodadek, Post Doc,  Professor and Vice Chairman of Chemistry at the Scripps Research Institute campus in Jupiter,:
 
"When the ruthenium absorbs visible light, it has to dump that energy to return to a normal state,” said Kodadek. “In the process, it produces an extremely reactive form of oxygen that rips apart whatever proteins it happens to encounterBasically, it destroys those proteins forever."
 
 
 This then explain (in parts or in totality) why Dr. McFarland's brilliant PDC is so good at delivering these spectacular results seen on NMIBC P#5 and P#6 (no recurrence) and, once again, in the Ph. 2 optimized group and why TLT was also able to demonstrate its ability to also destroy GBM cancer stem cells too.  
<< Previous
Bullboard Posts
Next >>